# Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

> **NCT02254044** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 7 (actual)

## Conditions studied

- Carcinoma, Squamous Cell

## Interventions

- **DRUG:** bivatuzumab mertansine

## Key facts

- **NCT ID:** NCT02254044
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-10
- **Primary completion:** 2004-11
- **Final completion:** —
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2014-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254044, "Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02254044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*